Holen Sie sich die Stockscreener-App
1.02
3.77%
-0.04
Handel nachbörslich:
1.00
-0.02
-1.96%
Schlusskurs vom Vortag:
$1.06
Offen:
$1.11
24-Stunden-Volumen:
94,308
Relative Volume:
0.44
Marktkapitalisierung:
$3.70M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.28M
KGV:
-0.3389
EPS:
-3.01
Netto-Cashflow:
$-9.78M
1W Leistung:
+8.51%
1M Leistung:
-28.17%
6M Leistung:
-54.46%
1J Leistung:
-87.12%
1-Tages-Spanne:
$1.0001
$1.12
1-Wochen-Bereich:
$0.95
$1.12
52-Wochen-Spanne:
$0.8601
$8.9686
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Firmenname
Ensysce Biosciences Inc
Sektor
Branche
Telefon
(858) 263-4196
Adresse
7946 IVANHOE AVENUE, LA JOLLA
Vergleichen Sie ENSC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
1.02 | 3.85M | 0 | -11.28M | -9.78M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ensysce Biosciences Inc Aktie (ENSC) Neueste Nachrichten
Ensysce Biosciences Annual Meeting: Share Issuance Approved, PF614 Phase III and FDA Designations Update - Defense World
Why Ensysce Biosciences Inc. stock is seen as undervaluedJuly 2025 Sector Moves & AI Based Trade Execution Alerts - ulpravda.ru
Why Ensysce Biosciences Inc. stock could be next big winnerWeekly Trade Report & AI Forecasted Stock Moves - ulpravda.ru
Ensysce Biosciences Shareholders Approve Key Corporate Actions - TipRanks
How Ensysce Biosciences Inc. stock compares to growth peersWeekly Gains Report & Safe Capital Growth Stock Tips - ulpravda.ru
How rising interest rates impact Ensysce Biosciences Inc. stockJuly 2025 Setups & Daily Technical Forecast Reports - ulpravda.ru
Can Ensysce Biosciences Inc. stock resist market sell offsQuarterly Risk Review & Step-by-Step Trade Execution Guides - ulpravda.ru
MarketsMedicine Hat News - FinancialContent
How Ensysce Biosciences Inc. stock reacts to Fed rate cutsSell Signals and Alerts & Low Cost Trading Plans - ulpravda.ru
ENSC: All proposals passed and clinical programs advanced, setting the stage for a pivotal year - TradingView — Track All Markets
Ensysce Biosciences, Inc.Common Stock (NQ: ENSC - FinancialContent
Ensysce’s PF614 Steps Forward in Phase 3 Post-Surgery Pain Trial: What Investors Should Watch - TipRanks
Ensysce Biosciences Issues Annual Shareholder Letter - The Globe and Mail
Ensysce Biosciences advances phase 3 trial for abuse-resistant opioid By Investing.com - Investing.com India
Inside a biotech developing pain pills with built-in overdose protection - Stock Titan
Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Up 188.9% in December - Defense World
Will Ensysce Biosciences Inc. stock maintain growth storyWeekly Profit Recap & Free Community Supported Trade Ideas - Улправда
Ensysce Biosciences’ Innovative Approach to Safer Opioid Use: A Clinical Study Update - MSN
What sentiment indicators say about Ensysce Biosciences Inc. stockTrade Entry Summary & Fast Momentum Entry Tips - Улправда
Why Ensysce Biosciences Inc. stock is considered a top pick2025 Trading Volume Trends & Weekly Stock Breakout Alerts - Улправда
How buybacks impact Ensysce Biosciences Inc. stock valueEarnings Performance Report & Community Shared Stock Ideas - Улправда
Can Ensysce Biosciences Inc. stock maintain operating margins2025 AllTime Highs & Verified Stock Trade Ideas - Улправда
Resistance Check: Can Ensysce Biosciences Inc. stock maintain operating marginsMarket Performance Report & High Return Trade Guides - Улправда
Ensysce Biosciences Earnings Notes - Trefis
EBIT per share of Ensysce Biosciences Inc. – OTC:ENSCW - TradingView — Track All Markets
ENSC enrolls first patient in critical phase 3 trial - MSN
Ensysce Biosciences initiates enrollment in Phase 3 trial of PF614 - MSN
Ensysce Biosciences enrolls first patient in phase 3 pain drug trial - Investing.com Australia
Should You Buy Ensysce Biosciences After Share Sale? - StocksToTrade
Is Ensysce Biosciences a Hidden Gem? - timothysykes.com
Ensysce Biosciences enrolls first patient in phase 3 pain drug trial By Investing.com - Investing.com South Africa
Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid - Corsicana Daily Sun
Ensysce Biosciences (NASDAQ: ENSC) starts Phase 3 PF614 trial in abuse-deterrent opioid - Stock Titan
How Ensysce Biosciences Inc. stock performs in interest rate cyclesQuarterly Profit Review & Real-Time Buy Signal Notifications - Newser
Why Ensysce Biosciences Inc. stock attracts high net worth investorsIPO Watch & Free Weekly Chart Analysis and Trade Guides - Newser
Ensysce (NASDAQ: ENSC) secures MPAR overdose tech patent protection to 2042 - Stock Titan
Is Ensysce Biosciences Inc. stock near bottom after declineEarnings Beat & Weekly High Conviction Trade Ideas - Newser
Will Ensysce Biosciences Inc. stock outperform international peersProfit Target & Verified Stock Trade Ideas - Newser
Ensysce Biosciences (ENSC) Stock Analysis Report | Financials & Insights - Benzinga
Earnings Beat: Why Ensysce Biosciences Inc. stock is seen as undervalued2025 Volatility Report & Fast Gaining Stock Reports - moha.gov.vn
Is Ensysce Biosciences, Inc. overvalued or undervalued? - Markets Mojo
Ensysce Biosciences Inc. (ENSC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
[PRE 14A] Ensysce Biosciences, Inc. Preliminary Proxy Statement - Stock Titan
Will Ensysce Biosciences Inc. stock benefit from AI adoption2025 Volatility Report & Community Shared Stock Ideas - newser.com
Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach - The Joplin Globe
Finanzdaten der Ensysce Biosciences Inc-Aktie (ENSC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):